Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of DX126-262 in HER2-positive unresectable locally advanced or recurrent/metastatic breast cancer
CTR20211871Phase 2Active
- Sponsor
- Hangzhou DAC Biotech
- Start
- Nov 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DX126-262 in breast cancer, sponsored by Hangzhou DAC Biotech. Started Nov 2021; status: active.
02
Drugs
DX126-262
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20211871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211871.